Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iain Gardner

Showing results (41-50 of 106) with videos related to

Pageof 11
Sort By:
Antibodies (Basel, Switzerland)|August 27, 2024
A Physiologically Based Pharmacokinetic Model Relates the Subcutaneous Bioavailability of Monoclonal Antibodies to the Saturation of FcRn-Mediated Recycling in Injection-Site-Draining Lymph NodesFelix Stader, Cong Liu, Abdallah Derbalah, et al.
Frontiers in Pharmacology|September 12, 2022
SimRFlow: An R-based workflow for automated high-throughput PBPK simulation with the Simcyp<sup>®</sup> simulatorHiba Khalidi, Anthonia Onasanwo, Barira Islam, et al.
Clinical Pharmacokinetics|December 10, 2024
Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug-Drug Interactions via Cytochromes P450: One Step Forward and Two Steps BackwardsIvan Tiryannik, Aki T Heikkinen, Iain Gardner, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 15, 2026
How can we overcome the pharmacokinetic challenges posed when conducting complex DDI studies?Iain Gardner, Eva Gil Berglund, Hannah M Jones, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 30, 2025
Correction: Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokineticsAbdallah Derbalah, Felix Stader, Cong Liu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 19, 2025
Physiologically based pharmacokinetic modeling of aldehyde oxidase drug-drug interactions mediated by erlotinibAki T Heikkinen, Mailys De Sousa Mendes, Mark A West, et al.
British Journal of Clinical Pharmacology|April 17, 2024
Administration mode matters for 5-fluorouracil therapy: Physiologically based pharmacokinetic evidence for avoidance of myelotoxicity by continuous infusion but not intravenous bolusChih-Jia Chao, Iain Gardner, Chun-Jung Lin, et al.
Reproductive Toxicology (Elmsford, N.Y.)|March 2, 2020
Development of a generic zebrafish embryo PBPK model and application to the developmental toxicity assessment of valproic acid analogsSégolène Siméon, Katharina Brotzmann, Ciaran Fisher, et al.
Reproductive Toxicology (Elmsford, N.Y.)|November 6, 2020
Corrigendum to "Development of a generic zebrafish embryo PBPK model and application to the developmental toxicity assessment of valproic acid analogs" [Reprod. Toxicol. 93 (2020) 219⬜229]Ségolène Siméon, Katharina Brotzmann, Ciarán Fisher, et al.
Metabolites|October 27, 2022
Performance Verification of CYP2C19 Enzyme Abundance Polymorphism Settings within the Simcyp Simulator v21Caroline Sychterz, Iain Gardner, Manting Chiang, et al.
Pageof 11

Showing results (41-50 of 106) with videos related to

Sort By:
Pageof 11
Antibodies (Basel, Switzerland)|August 27, 2024
A Physiologically Based Pharmacokinetic Model Relates the Subcutaneous Bioavailability of Monoclonal Antibodies to the Saturation of FcRn-Mediated Recycling in Injection-Site-Draining Lymph NodesFelix Stader, Cong Liu, Abdallah Derbalah, et al.
Frontiers in Pharmacology|September 12, 2022
SimRFlow: An R-based workflow for automated high-throughput PBPK simulation with the Simcyp<sup>®</sup> simulatorHiba Khalidi, Anthonia Onasanwo, Barira Islam, et al.
Clinical Pharmacokinetics|December 10, 2024
Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug-Drug Interactions via Cytochromes P450: One Step Forward and Two Steps BackwardsIvan Tiryannik, Aki T Heikkinen, Iain Gardner, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 15, 2026
How can we overcome the pharmacokinetic challenges posed when conducting complex DDI studies?Iain Gardner, Eva Gil Berglund, Hannah M Jones, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 30, 2025
Correction: Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokineticsAbdallah Derbalah, Felix Stader, Cong Liu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 19, 2025
Physiologically based pharmacokinetic modeling of aldehyde oxidase drug-drug interactions mediated by erlotinibAki T Heikkinen, Mailys De Sousa Mendes, Mark A West, et al.
British Journal of Clinical Pharmacology|April 17, 2024
Administration mode matters for 5-fluorouracil therapy: Physiologically based pharmacokinetic evidence for avoidance of myelotoxicity by continuous infusion but not intravenous bolusChih-Jia Chao, Iain Gardner, Chun-Jung Lin, et al.
Reproductive Toxicology (Elmsford, N.Y.)|March 2, 2020
Development of a generic zebrafish embryo PBPK model and application to the developmental toxicity assessment of valproic acid analogsSégolène Siméon, Katharina Brotzmann, Ciaran Fisher, et al.
Reproductive Toxicology (Elmsford, N.Y.)|November 6, 2020
Corrigendum to "Development of a generic zebrafish embryo PBPK model and application to the developmental toxicity assessment of valproic acid analogs" [Reprod. Toxicol. 93 (2020) 219⬜229]Ségolène Siméon, Katharina Brotzmann, Ciarán Fisher, et al.
Metabolites|October 27, 2022
Performance Verification of CYP2C19 Enzyme Abundance Polymorphism Settings within the Simcyp Simulator v21Caroline Sychterz, Iain Gardner, Manting Chiang, et al.
Pageof 11